Skip to main content
. 2017 May 19;8(42):73208–73218. doi: 10.18632/oncotarget.18021

Figure 1. Heterogeneity of MYC pathway activation in cancer.

Figure 1

The MYC pathway is activated in a patient with HNSCC by analysis of the cell lysate. MYC pathway activation was also detected in single CCR5+ breast cancer cells. (A) RNA-seq of a HNSCC lysate shows activation of multiple members in the MYC pathway. (B) Single-cell RNA-seq shows activation of MYC members through VEGFA and SP1. (C) Another single-cell RNA-seq shows activation of the MYC pathway through JUN and VEGFA. This heterogeneity of MYC pathway activation could explain why target therapies based on cell lysate results are often not effective or fail to control the cancers which contain multiple activation patterns of the MYC pathway. Red: upregulation; Green: down-regulation. Up- or down-regulation are calculated with fold difference of expression level cancer lysate/non-cancer lysate or cancer single cell/normal single-cell respectively. Darker color indicates higher fold changes.